Which is more profitable, Johnson & Johnson or UCB SA?

Johnson & Johnson keeps more of every sale as profit.

Which grows faster, Johnson & Johnson or UCB SA?

UCB SA grew its sales faster in recent years.

Which is cheaper, Johnson & Johnson or UCB SA?

Johnson & Johnson costs less for each unit of yearly profit (lower P/E).

Which has less debt, Johnson & Johnson or UCB SA?

UCB SA would need fewer years of earnings to pay off its debt.

Johnson & JohnsonJNJvs

UCB SAUCB.BR

Johnson & Johnson vs UCB SA stock

Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.

In one sentence

Johnson & Johnson is more profitable and is cheaper for its profits. UCB SA grows faster and has less debt.

Side by side

	Johnson & Johnson	UCB SA
	$688 billion	€56.5 billion
	28.5%	20.1%
	+2.7%	+12.0%
	25.7×	36.3×
	0.7 years	Net cash
	21.0%	11.2%
	2.3%	0.5%

Open Johnson & Johnson Open UCB SA

How we compare

Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.

More comparisons: Johnson & Johnson vs UnitedHealth · Johnson & Johnson vs Vertex Pharmaceuticals · Johnson & Johnson vs AbbVie · Johnson & Johnson vs Abbott Laboratories · UCB SA vs Eli Lilly · UCB SA vs Roche · UCB SA vs UnitedHealth · UCB SA vs AbbVie